Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Objective Response Rate|Trastuzumab Emtansine
Interventions: DRUG: Trastuzumab Emtansine (T-DM1)
Sponsor: The First Affiliated Hospital with Nanjing Medical University